Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) Cost of Revenue (2020 - 2022)

iBio (IBIO) has disclosed Cost of Revenue for 3 consecutive years, with $15000.0 as the latest value for Q2 2022.

  • On a quarterly basis, Cost of Revenue fell 97.7% to $15000.0 in Q2 2022 year-over-year; TTM through Jun 2022 was $216000.0, a 85.23% decrease, with the full-year FY2022 number at $216000.0, down 85.23% from a year prior.
  • Cost of Revenue was $15000.0 for Q2 2022 at iBio, down from $48000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $651000.0 in Q2 2021 to a low of $15000.0 in Q2 2022.
  • A 3-year average of $206300.0 and a median of $110000.0 in 2020 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: skyrocketed 473.26% in 2021, then crashed 97.7% in 2022.
  • iBio's Cost of Revenue stood at $211000.0 in 2020, then crashed by 46.45% to $113000.0 in 2021, then plummeted by 86.73% to $15000.0 in 2022.
  • Per Business Quant, the three most recent readings for IBIO's Cost of Revenue are $15000.0 (Q2 2022), $48000.0 (Q1 2022), and $113000.0 (Q4 2021).